Pasithea received a million-dollar financial award for its PAS-004 study

Announcement

Pasithea Therapeutics Corp., a leading clinical-level biotechnology company establishing a next-generation macrocyclic MEK inhibitor, PAS-004, is delighted to announce that its PAS-004 study in ALS patients has been awarded a Hoffman ALS Clinical Trial Award from the ALS Association with $1 million. This million-dollar award has been granted for further studies, examination and analysis that will meet the safety, tolerability and efficacy of PAS-004 for the treatment of the ALS patient population.

The financial award has not only led Pasithea towards strengthening its quality study but also empowered the initiatives of the company, as it's been recognised and counted by the ALS Association.

Excitement and responsibility of the healthcare leaders

The award comes with excitement and responsibility, especially the trust plays a major role in accomplishing a two-way success, one for the company and the other for the contribution to the vast healthcare sector. The ALS treatment will get a significant financial push to bring a required shift and progression into the PAS-004 study.

Pasithea is equally honored as well as responsible for delivering the best of the best study outcomes, utilising strong mind and money strength equally to achieve an excellent target that will serve improved treatment for ALS ALS-disturbed patient group.

The Chairman of Pasithea, Dr Lawrence Steinman, said, “We are honored and thankful to the ALS Association for recognising our sheer commitment to PAS-004. This support allows the efforts of the primary clinical trial of PAS-004 in patients with ALS. As this is a noteworthy profit for Pasithea, we are heading to deliver proven clarification that PAS-004 might be a robust MEK inhibitor for the treatment of as many indications encountered in future.”

“I am grateful to be able to continue working on the establishment of best-in-class, effective treatments for ALS.”

Lawrence added, “The PAS-004 focuses on a crucial molecule in the pathophysiology of motor neuron disease and has served to a meaningful and valuable results in the ALS peaked standard SOD mouse model. The PAS-004 is already in the clinic, proving its potential in advanced cancers and neurofibromatosis with its primary monotherapy efficacy signal and safety profile. We are waiting for PAS-004 to make its debut in the clinic for ALS, too, a disease that hasn’t yet met the advances in therapy.”

The CEO of Pasithea, Dr Tiago Reis Marques, also mentioned other leading treatment nutrients and their potential in serving best to the progression and development of ALS.